RDD Pharma

Treating Anorectal Diseases with Repurposed Drugs

Non Active, Apr 2020 due to acquisition

Company Overview

Snapshot

Founded in April 2008 by Nir Barak, RDD Pharma operates with 11–50 employees. The company has raised $17 million across 3 funding rounds from 6 investors. In November 2017, RDD Pharma secured Series B funding from Capital Point and OrbiMed.

Business overview

RDD Pharma is a specialty drug company focused on developing targeted pharmacological treatments for anorectal diseases such as anal fissures, fecal incontinence, and pruritus ani. The company's core approach involves repurposing existing drugs and combining them with proprietary drug-delivery technology to accelerate regulatory pathways while maintaining patent protection. RDD Pharma serves the pharmaceutical and healthcare industries, operating within the drug delivery, gastroenterology, and pharmaceuticals sectors.

Strategic signal

In October 2019, RDD Pharma merged with Innovate Biopharmaceuticals, Inc. This strategic consolidation aimed to combine RDD Pharma's expertise in anorectal disease treatments with Innovate's broader biopharmaceutical pipeline, signaling a move towards expanded market reach and integrated drug development efforts for investors.

Company Intelligence Q&A

What was a significant corporate event for RDD Pharma in late 2019?
In October 2019, RDD Pharma merged with Innovate Biopharmaceuticals, Inc., as reported by Beckers ASC and Globes.
Which investors participated in RDD Pharma's Series B funding round?
In November 2017, RDD Pharma raised Series B funding from investors including.
What regulatory milestone did RDD Pharma achieve for RDD-0315 in early 2019?
In February 2019, RDD Pharma received Fast Track Designation from the FDA for RDD-0315, intended for the treatment of fecal incontinence in spinal cord injury patients.
When did RDD Pharma announce IND clearance for RDD-0315?
In July 2018, RDD Pharma announced IND clearance to advance RDD-0315 for the treatment of fecal incontinence in patients with spinal cord injury.
Who was an early investor in RDD Pharma?
In July 2012, OrbiMed Healthcare Fund Management invested in RDD Pharma during its A Round funding.

External links